ImmunoScape is a clinical-stage, Singapore-headquartered biotechnology company focused on engineering T-cell receptor (TCR) therapeutics for solid tumors. Its proprietary deep-immunomics discovery engine and high-throughput TCR platform underpin a two-step “Seed and Boost” approach: first seeding patients with autologous T cells bearing a high-affinity WT1-specific TCR, then boosting those cells in vivo with an Immuno-STAT fusion protein that selectively expands and activates them. The company is preparing an investigator-initiated trial with a premier U.S. NCI-designated Comprehensive Cancer Center targeting WT1-positive ovarian, mesothelioma, pancreatic, colorectal and other hard-to-treat cancers, with first dosing expected by September 2026. ImmunoScape’s scientists will present supporting data at the 2026 AACR Annual Meeting, reflecting growing scientific validation. The business originated as a spin-out of Singapore’s A*STAR and maintains operations in both Singapore and California. Existing backers include Amgen Ventures and EDBI, and the company has now attracted a high-profile strategic investor in Leonardo DiCaprio. No revenue or user metrics were disclosed in the article.

Total raised

$39M

Funding rounds

4

Latest round

Equity

Latest activity

Sep 2022